Vera Therapeutics, Inc.(VERA)Earnings, Financials & Key RatiosVera Therapeutics, Inc. (VERA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the rapid depletion of cash reserves from $354.7 million to $114.4 million in a single quarter, combined with a $125.1 million quarterly operating loss, suggests significant near-term dilution risk for shareholders.
Vera Therapeutics, Inc. (VERA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Vera Therapeutics, Inc. (VERA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.69vs $1.33-27.2% | —vs $426,033 |
| Q1 2026 | Feb 26, 2026 | $1.39vs $1.34-3.7% | — |
| Q4 2025 | Nov 5, 2025 | $1.26vs $1.20-5.0% | — |
| Q3 2025 | Aug 5, 2025 | $1.20vs $0.82-46.3% | — |
Recent stock market news and headlines for Vera Therapeutics, Inc. (VERA)
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares up 6.2% in afternoon trading.
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link.
Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Key metrics vs top competitors for Vera Therapeutics, Inc. (VERA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.96 | $3.08B | -9.22 | — | — | -50.71% | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $42.13 | $4.88B | -13.21 | — | — | -71.31% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — |
Vera Therapeutics, Inc. (VERA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Vera Therapeutics, Inc. (VERA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 9, 2026·SEC
Feb 26, 2026·SEC
Get notified when VERA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vera Therapeutics, Inc. (VERA) stock FAQ — growth, dividends, profitability & financials explained
Vera Therapeutics, Inc. (VERA) reported a net loss of $369.0M for fiscal year 2025.
Vera Therapeutics, Inc. (VERA) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
Vera Therapeutics, Inc. (VERA) had negative free cash flow of $187.1M in fiscal year 2025, likely due to heavy capital investments.
